|
|
18 MAY 2025 |
||
|
14.30 - 14.40 |
OPENING REMARKS OF EHOC 2025 Birol Güvenç, Serdar Bedii Omay, Giuseppe Saglio |
||
|
SESSION 1 - Opening Session |
Chairs: Rudiger Hehlmann - Bülent Zülfikar |
||
|
14.40 - 14.55 |
Mission to Mars: Radiation Risk For Interplanetary Travel |
Robert Gale |
|
|
14.55 - 15.10 |
Some Nobel Prizes That Shaped Hematology |
Emin Kansu |
|
|
15.10 - 15.30 |
History of Blood Transfussion |
Tanju Atamer |
|
|
15.30 - 15.45 |
History of Acute Lymphoblastic Leukemia |
Dieter Hoelzer |
|
|
15.45 - 16.00 |
From DigiBioPharma to NeXPharma: On the Brink of Digital and Biological Integration in Hematology (Pharma 4.9 → Pharma 5.0) |
Birol Güvenç |
|
|
16.00 - 16.15 |
The History of Chronic Myeloid Leukemia: From Arsenic to Asciminib |
Rudiger Hehlmann |
|
|
16.15 - 16.25 |
Q&A |
|
|
|
16.25 - 16.50 |
COFFEE BREAK |
||
|
|
SESSION 2 - Management of Chronic Lymphoproliferative Diseases & Indolent Lymphomas |
CHAIRS: Gianluca Gaidano - Pelin Aytan |
|
|
16.50 - 17.10 |
How I Treat T-Cell Lymphoma |
Ana Maria Sureda Balari |
|
|
17.10 - 17.30 |
How To Manage CLL with Restricted Resources |
Gianluca Gaidano |
|
|
17.30 - 17.50 |
New Drugs for CLL |
Ahmad Ibrahim |
|
|
17.50 - 18.10 |
How I Treat Marginal Zone Lymphoma |
Irina Panovska-Stavridis |
|
|
18.10 - 18.25 |
How I Treat Follicular Lymphoma |
Umut Yılmaz |
|
|
|
Q&A |
|
|
|
|
SESSION 3 - Management of Aggressive Lymphomas |
CHAIRS: Khaled Halehleh - Vahap Okan |
|
|
18.25 - 18.45 |
Novel Therapies for Relapsed/Refractory Aggressive Lymphomas |
Huseyin Bekoz |
|
|
18.45 - 19.05 |
Diffuse Large Cell Lymphomas with Restricted Resources |
Suzana Krasniqi |
|
|
19.05 - 19.25 |
Mantle Cell Lymphoma |
Massimo Federico |
|
|
19.25 - 19.45 |
Treatment for Hodgkin Lyphomass with Restricted Resources |
Khaled Halahleh |
|
|
19.45 - 20.00 |
Q&A |
|
|
|
19 MAY 2025 |
|
||
|
07.30 - 08.30 |
Oral Communications Sessions |
CHAIRS: Gamze Tanrıöver - Fatih Erbey |
|
|
07:30 – 07:40 |
Characteristics Of Hematological Manifestations İn Patients With Systemic Lupus Erythematosus: Single Center Experience |
Gül Sandal Uzun |
|
|
07:40 – 07:50 |
Neuron Specıfıc Enolase Positive Ovarian Intermediate Grade Sertoli-Leydig Cell Tumor: A Rare Case Report |
Şule Çalışkan Kamış |
|
|
07:50 – 08:00 |
Two Cases Of Primary Amyloidosis Presenting With Vertebral Amyloidoma |
Ebru Kavak Yavuz |
|
|
08:00 – 08:10 |
T-Cell Lymphoma Diagnosis And Treatment in Kosovo, A Cross Sectional Study |
Adriatik Berisha |
|
|
08:10 – 08:20 |
Effıcacy Of Roxadustat in Chronic Kidney Disease Patients Not On Dialysis With Anemia: Systematic Review And Meta-Analysis Of Randomized Controlled Trials |
Ahmet Sarıcı |
|
|
08:20 – 08:30 |
Prognostic Implications Of High-Risk Genetic Mutations In Multıple Myeloma Patients Undergoıng Second Autologous Stem Cell Transplant |
Taner Tan |
|
|
|
SESSION 4 - Management of Myeloma & Plasma Cell Dyscrasias |
CHAIRS: Claudio Cerchione – Berksoy Şahin |
|
|
08.30 - 08.50 |
First Line Therapy |
Evangelos Terpos (Virtual) |
|
|
08.50 - 09.10 |
Treatment of Relapsed Refractory Multiple Myeloma |
Claudio Cerchione |
|
|
09.10 - 09.30 |
How I Manage Fragile Patients in Multiple Myeloma |
Alpay Yeşilaltay |
|
|
09.30 - 09.50 |
Upcoming Treatments for Multiple Myeloma |
Claudio Cerchione |
|
|
09.50 - 10.05 |
Q&A |
|
|
|
10.05 - 10.35 |
COFFEE BREAK |
||
|
10.35 - 11.05 |
ABDİ İBRAHİM SATALITE SYMPOSIUM Second-line treatment in CML: “Mylorge ile Yolunda İlerle.." Chair : Şebnem İzmir Güner; |
||
|
SESSION 5 - Management of Chronic Myeloproliferative Disorders |
Chairs: Rudiger Hehlmann - Mehmet Ali Özcan |
||
|
11.05 - 11.25 |
Short and Long Term Toxicities of TK Treatments |
Tomasz Sacha |
|
|
11.25 - 11.45 |
Treatment of CML with Limited Resources |
Giuseppe Saglio |
|
|
11.45 - 12.05 |
New Methods To Monitor CML Patients For TFR |
Naeem Chaudhry |
|
|
12.05 - 12.25 |
How To Manage CML in Pregnancy |
Tomasz Sacha |
|
|
12.25 - 12.45 |
Prediction of the Risk of Leukemia Development in Aged Healthy Population; Implementation in the Public Health System |
Francesco Frassoni |
|
|
12.45 - 13.00 |
Q&A
|
|
|
|
13.00 - 14.00 |
LUNCH |
||
|
|
SESSION 6 - Management of PH Negative Myeloproliferative Diseases |
CHAIRS: Tariq Mughal - Sinem Namdaroğlu |
|
|
14.00 - 14.20 |
Eosinophilia Updates |
Hanan Hamed |
|
|
14.20 - 14.40 |
New Drugs for Myelofibrosis |
Tariq Mughal |
|
|
14.40 - 15.00 |
Neutrophilia |
Hanan Hamed |
|
|
15.00 - 15.20 |
Treatment for Chronic Myeloproliferative Disorders with Limited Resources |
Tariq Mughal |
|
|
15.20 - 15.35 |
Q&A |
|
|
|
|
SESSION 2 - Management of Acute Lymphocytic Leukemias |
CHAIRS: Dieter Hoelzer - Şehmus Ertop |
|
|
15.35 - 15.55 |
How I Treat Ph+ ALL |
Robin Foa |
|
|
16.15 - 16.35 |
How I Treat Non Ph+ ALL |
Mahmut Bakır Koyuncu |
|
|
16.35 - 16.55 |
How I Treat T-ALL |
Ali Bazarbachi (Virtual) |
|
|
16.55 - 17.15 |
What We Can Learn From The Treatment of the Pediatric ALL for Adult Patients |
Francesco Saglio |
|
|
17.15 - 17.30 |
Q&A |
|
|
|
17.30 - 18.00 |
COFFEE BREAK |
||
|
|
SESSION 3 - Management of Acute Myeloid Leukemias |
CHAIRS: Serdar Bedii Omay - Gülsüm Özet |
|
|
18.00 - 18.20 |
How I Treat Relapsed Refractory ALL |
Giovanni Martinelli (Virtual) |
|
|
18.20 - 18.40 |
How I Treat Fragile and Elderly Patients with AML |
Semra Aydin |
|
|
18.40 - 19.00 |
Clinical Usefullness of MRD in AML |
Mehreen Ali Khan |
|
|
19.00 - 19.20 |
Which is The Best Treatment for AML with Restricted Resources |
Mipsang Lama |
|
|
20.00 - 20.15 |
Q&A |
|
|
|
20.15 - 21.45 |
POSTER WALK & RECOGNITIONS & AWARDS |
||
|
PP - 01 |
Validation Of Long-Term Handling And Storage Conditions For Hematopoietic Stem Cell Products For Autologous Transplants |
Ahmed Al Bahrani |
|
|
PP – 02 |
Methotrexate-Assocıated Stevens-Johnson Syndrome And Toxıc Epıdermal Necrolysıs: Two Case Reports |
Serdar Bedii Omay |
|
|
PP – 03 |
Treatment Management In Multıple Myeloma Wıth Renal Dısorder
|
Meryem Şener |
|
|
PP – 04 |
A Case Of Thrombocytosıs And Haemothorax in A Patient With Itp Followıng Romiplostim Use |
Ali Turunç |
|
|
PP – 05 |
The Success Lies On Clinical Suspect: The Synchronous Cancers Presenting As Pulmonary And Vertebral Mass Lesıons |
Ulviyya Hasanzade |
|
|
PP – 06 |
Clinico-Biological Profile And Management Of Chronıc Lymphocytic Leukemia |
Vasile Musteata |
|
|
PP – 07 |
Rituximab With Involved Field Irradiation For Early-Stage Diffuse Large Cell Lymphoma |
Marwa Abdelgawad |
|
|
PP – 08 |
A Fusion Of Nup214 To Abl1 On Amplified Episomes in T-Cell Acute Lymphoblastic Leukemia: Case Report And Literature Revıew |
Jiantuo Liu |
|
|
PP – 09 |
Cytogenetic Features Of B-Cell Acute Lymphoblastic Leukemia With Intrachromosomal Amplification Of Chromosome 21 |
Jiantuo Liu |
|
|
PP - 10 |
A New Look At The Treatment Of Patients With Acute Leukemia |
Mireldar Babayev |
|
|
PP – 11 |
Low-Dose Cytarabne Plus Sorafenib in An Elderly Patient With Acute Myeloid Leukemia |
Tural Mahmudov |
|
|
PP – 12 |
A Case Of Familial Porfiria |
Laman Hamidova |
|
|
PP – 13 |
Assesment Of Interphase Fluorescence In Sıtu Hybrıdızatıon (Fısh) Test In A Patıent Wıth Multıple Myeloma : Experıence Of Our Medıcal Genetıcs Department. |
Fatma Turki |
|
|
PP – 14 |
Immunophenotypıc Characterıstıcs And Treatment Outcome Of T-Acute Lymphoblastıc Leukemıa In Adults; An Iraqı Center Experıence |
Abdulsalam Al Ani |
|
|
PP – 15 |
Chıc2 Deletıon-Assocıated Hypereosınophılıa And Subsequent Jak2 V617f Posıtıve Thrombocytosıs |
Mürüvvet Seda Aydın |
|
|
PP – 16 |
Unexpected Spontaneous Regressıon In Cll After Letrozole Treatment: Coıncıdence Or Connectıon? |
Ennur Ramadan |
|
|
PP – 17 |
Correlatıon Of Сd10+ B-Lymphocytes And Plasma Cells Wıth Outcome In Breast Cancer |
Svetlana Chulkova |
|
|
PP – 18 |
Two Cases Of Primary Amyloidosis Presenting With Vertebral Amyloidoma |
Ebru Kavak Yavuz |
|
|
PP – 19 |
Cases Of Primary Cutaneous Anaplastic Large Cell Lymphoma Treated With Systemic Or Local Therapy |
Müzeyyen Aslı Ergözoğlu |
|
|
PP - 20 |
Dynamıc Balance Evaluatıon In Chıldren Wıth Acute Lymphoblastıc Leukemıa Undergoıng Consolıdatıon Therapy |
Fulya İpek Erdem |
|
|
PP - 21 |
Investıgatıon Of Postural Control In Chıldren Wıth Acute Lymphoblastıc Leukemıa |
Fulya İpek Erdem |
|
|
PP - 22 |
Outcomes Of Allogeneıc Stem Cell Transplantatıon In Patıents Wıth Acute Myeloıd Leukemıa: A Sıngle-Center Experıence |
Serdar Bedii Omay |
|
|
PP - 23 |
Investıgatıon Of The Relatıonshıp Between Compassıon And Burnout Among Hematologist And Oncologist |
Nisa Aliş |
|
|
PP - 24 |
Polyradıculopathy Followıng Car T Cell Therapy For Lymphoıd Malıgnancıes, Dıagnostıc Challenges: A Report Of 3 Cases |
Alfadıl Haroon |
|
|
PP - 25 |
Lysozyme-Induced Nephropathy In Cmml: A Rare But Sıgnıfıcant Complıcatıon Requırıng Early Recognıtıon And Interventıon |
Alfadıl Haroon |
|
|
PP - 26 |
Analysıs Of Response To Fırst-Lıne Therapy Wıth Imatınıb In Azerbaıjanı Cml Patıents |
Aytan Shirinova |
|
|
PP - 27 |
Treatment Of Blast Phase Myeloproliferative Neoplasm With The Combination Of Azacitidine, Venetoclax And Ruxolitinib. |
Fidan Khalilova |
|
|
PP - 28 |
Long-Term And Late Effects Of Chemotherapy In Chıldhood Acleukemıa And Theır Management Sıngle Instıtutıon Observatıonute Lymphoblastıc |
Konul Baghırova |
|
|
PP - 29 |
Acute Lymphoblastic Leukemia Diagnosed Four Years After HSCT in a Beta Thalassemia Patient: A Clinical Case |
Huseyn Kerimov |
|
|
PP - 30 |
Outcomes Of Dıffuse Large B-Cell Lymphoma In Older Adults Treated In Resource-Constraıned Settıngs |
Natasha Ali |
|
|
PP – 31 |
Clınıcal Presentatıon And Outcomes Of Patıents Wıth Myelodysplastıc Syndrome Introductıon |
Jehanzeb Ur Rehman |
|
|
PP – 32 |
Landscape Of Somatıc Mutatıons Of Myeloprolıferatıve Neoplasms In Pakıstanı Patıents |
Mehreen Ali Khan |
|
|
PP – 33 |
A Rare Case Of Diffuse Large B-Cell Lymphoma Presenting With Chronic Gastrointestinal Symptoms: A Diagnostic Challenge |
Bulut Sat |
|
|
PP – 34 |
Acute Myeloid Leukemia Presenting As Isolated Myeloid Sarcoma: A Case Report |
Elif Canbolat Hırfanoğlu |
|
|
PP – 35 |
Cold Agglutinin Disease İn A Patient With Waldenström’s Macroglobulinemia: A Diagnostic And Therapeutic Challenge |
Ceren Kısa |
|
|
PP – 36 |
Reversal Of Accelerated-Phase Cml With High Blast Count Following 5+2 Chemotherapy And Dasatinib: A Case Report |
Büşra Akdoğan |
|
|
PP – 37 |
Therapeutic Apheresis For Epidermolysis Bullosa And Secondary Thrombocytosis İn Norwegian Scabies: A Case Report |
Mine Ezgi Payaslı |
|
|
PP – 38 |
Transformation Of Follicular Lymphoma İnto Diffuse Large B-Cell Lymphoma After A Decade Of Remission: A Case Report |
Elif Canbolat Hırfanoğlu |
|
|
PP – 39 |
Impact of Lenalidomide Maintenance Dosage on Survival Outcomes in Multiple Myeloma |
Zeynep Kürüm |
|
|
|
20 MAY 2025 |
||
|
08:10 - 09.00 |
Oral Communications Sessions |
Chairs: Burhan Turgut - Güven Çetin |
|
|
08:10 – 08:20 |
Prımary Adrenal And Female Genıtal Extranodal Lymphomas |
Müzeyyen Aslı Ergözoğlu |
|
|
08:20 – 08:30 |
Rısk Of Developıng Oncohematologıcal Dıseases In Indıvıduals Infected Wıth Hepatıtıs C And B Vırus
|
Gunel Aliyeva |
|
|
08:30 – 08:40 |
Genetıc Profıle Of Prımary Myrlofıbrosıs Patıents In Azerbıjan |
Madad Abbasov |
|
|
08:40 – 08:50 |
Prognostic Value Of CD56 Expression İn Children With Acute Myeloid Leukemia. |
Reyhan Aliyeva |
|
|
08:50 – 09:00 |
Real World Outcomes Of Hypomethylating Agents And Venetoclax Combination Therapy İn Acute Myeloid Leukemia And Myelodysplastic Syndrome- Single Center Experience From A Resource Limited Country |
Maryam Khan |
|
|
SESSION 9 - What’s New in Cancer Immunotherapy |
Chairs: Jean François Rossi - Ismail Elalamy |
||
|
09:00 – 09:20 |
Alternative New Ways in Cellular Immune Therapies |
Martin Villalba (Virtual) |
|
|
09:20 – 09:40 |
Has the arrival of CAR T-cells Changed the Indications of Allogeneic Transplantation |
Manel Juan (Virtual) |
|
|
09:40 – 10:00 |
Bi-Specific Monoclonal Antibodies in Hematology-Oncology |
Jean François Rossi |
|
|
10:00 – 10:20 |
Thromboses Risk and Immune Therapy |
Ismail Elalamy |
|
|
10:20 – 10:40 |
PNH and Thrombosis |
Zoubida Tazi (Virtual) |
|
|
10:40 – 11:00 |
Round Table: T-Cell Engagers and CAR-T Cell Therapy |
All |
|
|
11:00 – 11:10 |
Q&A |
|
|
|
11.10 - 11.40 |
COFFEE BREAK |
||
|
11.40 - 12.00 |
Life Time Achivement |
Introduction: Giuseppe Saglio - Award Recipient: Zeba Aziz |
|
|
|
SESSION 10 - Management of Myelodysplastic Syndromes |
Chairs: Hasan Atilla Özkan - Mehmet Ali Uçar |
|
|
12.00 - 12.20 |
MDS Diagnosis? Still by Bone Marrow Examination ? |
Moshe Mittelman (Virtual) |
|
|
12.20 - 12.40 |
New Drugs for MDS |
Daniela Cilloni |
|
|
12.40 - 13.00 |
How To Treat MDS with Limited Resources |
Argiris Symeonidis |
|
|
13.00 - 13.30 |
New Reccomendations For The MDS Treatment |
Mehmet Yılmaz |
|
|
13.30 - 13.35 |
Q&A |
|
|
|
13.35 |
CLOSING REMARKS |
||
